Appointment dossier — Pancreatic Cancer
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Pancreatic Cancer
- Fuzuloparib — Review evidence · 1 positive · PMID 34118019
- Relacorilant — Review evidence · 1 positive · PMID 42334771
- Gemcitabine — Animal evidence · 0 positive / 1 negative-mixed · PMID 34274382
“Positive” means a study reported a positive result — most are early lab/animal work that may not translate to people.
Open recruiting trials (18)
- NCT06368063 · Phase 4 — The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer (China)
- NCT05268692 · Phase 2 / Phase 3 — Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP (Japan)
- NCT03556228 · Phase 1 / Phase 2 — VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma (United States)
- NCT06483555 · Phase 1 / Phase 2 — Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel (United States)
- NCT07539155 · Phase 1 / Phase 2 — Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer (United States)
- NCT07784374 · Phase 2 — A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation (China)
- NCT07692750 · Phase 1 / Phase 2 — IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer (China)
- NCT06821048 · Phase 1 — Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors (China)
- NCT05391126 — GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care (United States)
- NCT07557225 — 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors (China)
- NCT05424159 — Ablative Carbon Ion Radiotherapy With Pencil Beam Scanning for Locally Advanced Unresectable Pancreatic Cancer (China)
- NCT06564571 — Artificial Intelligence in Endoscopic Ultrasound (United States)
- NCT06803771 — Surveillance of Pancreatic Health After Diabetes Diagnosis (United Kingdom)
- NCT06943521 · Phase 1 / Phase 2 — A Study of MT-4561 in Patients With Various Advanced Solid Tumors (United States)
- NCT06405490 · Phase 2 — NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC (China)
- NCT05932862 · Phase 1 — A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors (United States)
- NCT04999761 · Phase 1 — AB122 Platform Study (Japan)
- NCT04706910 · Phase 3 — 18F-DOPA II - PET Imaging Optimization (Canada)
Most-relevant first: trials that name Pancreatic Cancer, then broader trials you may still qualify for. 896 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
For each medicine above, search manufacturer and nonprofit programs at medicineassistancetool.org.
Questions to ask your oncologist
- Of the open trials I found (for example NCT06368063), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?